144 related articles for article (PubMed ID: 21691891)
1. Ocular pharmacokinetic study using T₁ mapping and Gd-chelate- labeled polymers.
Shi X; Liu X; Wu X; Lu ZR; Li SK; Jeong EK
Pharm Res; 2011 Dec; 28(12):3180-8. PubMed ID: 21691891
[TBL] [Abstract][Full Text] [Related]
2. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging.
Kim H; Robinson MR; Lizak MJ; Tansey G; Lutz RJ; Yuan P; Wang NS; Csaky KG
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2722-31. PubMed ID: 15277497
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of gadolinium 2,5-BPA-DO3A, a new macrocyclic hepatobiliary chelate, in normal liver and metastatic disease on high field magnetic resonance imaging.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1996 Jan; 31(1):11-6. PubMed ID: 8850360
[TBL] [Abstract][Full Text] [Related]
4. Polyion complex micelle MRI contrast agents from poly(ethylene glycol)-b-poly(l-lysine) block copolymers having Gd-DOTA; preparations and their control of T(1)-relaxivities and blood circulation characteristics.
Shiraishi K; Kawano K; Maitani Y; Yokoyama M
J Control Release; 2010 Dec; 148(2):160-7. PubMed ID: 20804796
[TBL] [Abstract][Full Text] [Related]
5. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
[TBL] [Abstract][Full Text] [Related]
6. Gd accumulation in tissues of healthy mice upon repeated administrations of Gadodiamide and Gadoteridol.
Di Gregorio E; Iani R; Ferrauto G; Nuzzi R; Aime S; Gianolio E
J Trace Elem Med Biol; 2018 Jul; 48():239-245. PubMed ID: 29773187
[TBL] [Abstract][Full Text] [Related]
7. Gadolinium Retention in Erythrocytes and Leukocytes From Human and Murine Blood Upon Treatment With Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging.
Di Gregorio E; Furlan C; Atlante S; Stefania R; Gianolio E; Aime S
Invest Radiol; 2020 Jan; 55(1):30-37. PubMed ID: 31503081
[TBL] [Abstract][Full Text] [Related]
8. Quantification and Assessment of the Chemical Form of Residual Gadolinium in the Brain After Repeated Administration of Gadolinium-Based Contrast Agents: Comparative Study in Rats.
Frenzel T; Apte C; Jost G; Schöckel L; Lohrke J; Pietsch H
Invest Radiol; 2017 Jul; 52(7):396-404. PubMed ID: 28125438
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and tissue retention of (Gd-DTPA)-cystamine copolymers, a biodegradable macromolecular magnetic resonance imaging contrast agent.
Wang X; Feng Y; Ke T; Schabel M; Lu ZR
Pharm Res; 2005 Apr; 22(4):596-602. PubMed ID: 15846467
[TBL] [Abstract][Full Text] [Related]
10. MRI study of subconjunctival and intravitreal injections.
Li SK; Hao J; Liu H; Lee JH
J Pharm Sci; 2012 Jul; 101(7):2353-63. PubMed ID: 22473517
[TBL] [Abstract][Full Text] [Related]
11. Distribution and clearance of retained gadolinium in the brain: differences between linear and macrocyclic gadolinium based contrast agents in a mouse model.
Kartamihardja AA; Nakajima T; Kameo S; Koyama H; Tsushima Y
Br J Radiol; 2016 Oct; 89(1066):20160509. PubMed ID: 27459250
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats.
Tweedle MF; Wedeking P; Kumar K
Invest Radiol; 1995 Jun; 30(6):372-80. PubMed ID: 7490190
[TBL] [Abstract][Full Text] [Related]
13. Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents: Differences in Long-Term Biodistribution and Excretion.
Lancelot E
Invest Radiol; 2016 Nov; 51(11):691-700. PubMed ID: 27175546
[TBL] [Abstract][Full Text] [Related]
14. Impact of Treatment With Chelating Agents Depends on the Stability of Administered GBCAs: A Comparative Study in Rats.
Boyken J; Frenzel T; Lohrke J; Jost G; Schütz G; Pietsch H
Invest Radiol; 2019 Feb; 54(2):76-82. PubMed ID: 30358694
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy.
Gibby WA; Gibby KA; Gibby WA
Invest Radiol; 2004 Mar; 39(3):138-42. PubMed ID: 15076005
[TBL] [Abstract][Full Text] [Related]
16. Brain distribution of MRI contrast media in rats after intracisternal injection.
Allard M; Kien P; Caille JM; Bonnemain B; Simonnet G
J Neuroradiol; 1987; 14(4):383-7. PubMed ID: 3131496
[No Abstract] [Full Text] [Related]
17. A new biodegradable and biocompatible gadolinium (III) -polymer for liver magnetic resonance imaging contrast agent.
Xiao Y; Xue R; You T; Li X; Pei F
Magn Reson Imaging; 2015 Jul; 33(6):822-8. PubMed ID: 25839395
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy.
White GW; Gibby WA; Tweedle MF
Invest Radiol; 2006 Mar; 41(3):272-8. PubMed ID: 16481910
[TBL] [Abstract][Full Text] [Related]
19. Reductive microenvironment responsive gadolinium-based polymers as potential safe MRI contrast agents.
Guo S; Xiao X; Wang X; Luo Q; Zhu H; Zhang H; Li H; Gong Q; Luo K
Biomater Sci; 2019 Apr; 7(5):1919-1932. PubMed ID: 30773580
[TBL] [Abstract][Full Text] [Related]
20. Arterial concentration profiles of two blood pool agents and Gd-DOTA after intravenous injection in rabbits.
Corot CA; Violas X; Robert P; Port M
Acad Radiol; 2002 May; 9 Suppl 1():S137-9. PubMed ID: 12019850
[No Abstract] [Full Text] [Related]
[Next] [New Search]
